Pharmaceutical company
Appears in 20 stories · Last updated Oct 27, 2026
Launched Awiqli nationwide on August 11, 2026, and won FDA approval for children aged 10 and older on October 23, 2026
On March 26, the FDA approved Awiqli, the first once-weekly basal insulin, for adults with type 2 diabetes. It cuts basal insulin shots from 365 to 52 a year.
Updated 6 days ago
Main rival; markets oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic, Wegovy)
Millions with type 2 diabetes manage blood sugar with daily injections. Lilly's Foundayo is a pill that could replace them, and in its largest trial it matched insulin on heart safety while cutting weight and blood sugar more.
Updated Oct 18
Marks Rybelsus, the peptide oral GLP-1 with fasting requirements
Injectable GLP-1 drugs like Ozempic need needles; the only oral option, Rybelsus, must be taken on an empty stomach. Hengrui's safiglipron is a once-daily pill that works with food. Two phase 3 trials published this fall show it cuts blood sugar in both early diabetes and in patients uncontrolled on metformin.
On track to launch CagriSema early 2027
Adults with obesity and type 2 diabetes who took Eli Lilly's experimental EloraTZP lost an average of 23.3% of their body weight over 48 weeks — well beyond the 14.8% lost by those on tirzepatide alone, the drug sold as Zepbound. The combination pairs tirzepatide, a dual GIP and GLP-1 receptor agonist, with eloralintide, a selective amylin receptor agonist, engaging three appetite-regulating hormone pathways at once.
As of October 2026: Licensee of HRS-1596; global leader in GLP-1 therapies
Novo Nordisk will pay China's Hengrui Pharma $300 million upfront to license an experimental weight-loss pill designed for once-weekly use. The $2.6 billion total is a ceiling tied to development and sales milestones; the upfront is the only cash on signing, and it waits on US antitrust clearance.
Updated Oct 1
As of September 2026: Competitor; markets semaglutide as Ozempic and Wegovy
Roche's experimental once-weekly diabetes injectable cut blood sugar and body weight in a 48-week phase 2 trial announced September 22. Patients on the highest 24 mg dose saw HbA1c drop 2.65 percentage points and weight fall 15.5%.
Updated Sep 22
As of August 2026: Maker of semaglutide (Ozempic, Wegovy)
The FDA approved tirzepatide (Mounjaro) on August 28 to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk. The decision rests on SURPASS-CVOT, a 13,000-patient trial that found tirzepatide matched an older GLP-1 medicine, dulaglutide (Trulicity), on major heart events, with an estimated 8% lower rate.
Updated Aug 29
As of August 2026: Developer of denecimig; awaiting FDA decision
People with hemophilia A can bleed for hours from a small cut and bleed inside their joints for no clear reason. Novo Nordisk says its experimental injection, denecimig, kept most patients bleed-free in a long-term trial: about 71% of adults and teens and about 89% of children had zero treated bleeds.
Updated Aug 11
As of May 2026: GLP-1 market leader facing growing competition and declining sales forecasts
Kailera Therapeutics just pulled off the largest biotech initial public offering in history, raising $625 million and watching its shares surge 62.5% on the first day of trading. The company, founded less than two years ago with drugs licensed from a Chinese pharmaceutical firm, is now valued at roughly $3.5 billion — without a single approved product. That a startup built entirely around next-generation obesity drugs can command this kind of investor enthusiasm tells you where the pharmaceutical industry's center of gravity has shifted.
Updated May 31
As of May 2026: First-mover in oral GLP-1 obesity pills, now facing direct competition
For two years, the most effective weight-loss drugs on the market required a weekly injection, but that barrier is now falling. Eli Lilly began shipping Foundayo on April 6, 2026 — just five days after FDA approval in a record 50-day review — making it the first oral GLP-1 pill with no food or water restrictions. At $149/month (or $25 with insurance), it's 85% cheaper than injectables.
Updated May 30
As of May 2026: Manufacturer of Ozempic, Wegovy, and Saxenda; dominant GLP-1 market player
More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner.
As of May 2026: Market leader in GLP-1 obesity drugs; facing emerging competition
The biggest knock against blockbuster weight-loss drugs like semaglutide is that up to 40% of weight lost is lean tissue (muscle and bone), not fat. New therapies entering trials target genes to spare muscle.
As of May 2026: Patent holder defending market share against 40+ generic competitors in India
Only 200,000 of India's roughly 250 million people living with obesity have ever taken a GLP-1 receptor agonist—the class of drugs that includes Novo Nordisk's blockbuster Ozempic and Wegovy. On March 21, the day after Novo's last Indian patent expired, more than 40 companies began selling generic semaglutide at prices as low as 1,290 rupees a month (about $15, compared to $100–175 for the branded versions). It is the largest single-day generic launch in Indian pharmaceutical history.
As of May 2026: Manufacturer of semaglutide (Ozempic, Wegovy)
Drugs originally designed to control blood sugar and reduce weight may also protect the brain. A study of 95,490 people in Sweden, published in The Lancet Psychiatry on March 22, 2026, found that semaglutide (the compound in Ozempic and Wegovy) reduced psychiatric hospitalizations, worsening depression, and substance-use crises.
As of May 2026: Leads GLP-1 market with Wegovy injections and oral semaglutide ahead of Lilly's Foundayo entry
For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.
As of May 2026: Maker of Ozempic and Wegovy; not pursuing dedicated addiction trials
Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A March 4 BMJ study of more than 600,000 U.S. veterans found GLP-1 users were 14 percent less likely to develop a new substance use disorder.
As of May 2026: Maker of semaglutide; primary commercial stakeholder
Patients on Ozempic and Wegovy typically lose about 15% of their body weight, then stall around 14 months in. On May 25, NIH researchers in Nature Metabolism reported what may be happening inside the brain to cause that stall, and a way to keep the drug working longer.
Updated May 25
As of May 2026: Maker of semaglutide (Ozempic, Wegovy), one of the drugs studied
A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic led the study. Researchers compared GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.
Updated May 24
As of May 2026: Implementing additional insulin price cuts in 2026
On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.
Updated May 19
As of May 2026: Launched first oral GLP-1 weight loss pill; negotiating BALANCE participation
Medicare has been banned from covering weight loss drugs since 2003. CMS launched BALANCE in December 2025, a voluntary model offering $50-per-month Ozempic and Wegovy access for 10% of Medicare enrollees starting July 2026.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
